birinapant

crysalechain

zgct 发表于 2015-4-18 10:17
试药族”每次可获报酬上千元

拿自己的身体做试验，敢于奉献的人很少吧。太冒险了，钱再多也不好办吧。

newchinabok

birinapant师兄好不好

StephenW

TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA (pembrolizumab) in Solid Tumors
Published Online: Monday, April 20, 2015
Follow Pharmacy_Times:
PRESS RELEASE

MALVERN, Pa. & KENILWORTH, N.J.--(BUSINESS WIRE)--TetraLogic Pharmaceuticals Corporation (Nasdaq: TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today they have entered into an oncology clinical study collaboration. The companies will collaborate on a Phase 1 study to evaluate the safety and efficacy of birinapant, TetraLogic’s SMAC-mimetic, in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with relapsed or refractory solid tumors. The study is expected to begin in late 2015.

KEYTRUDA and birinapant target different elements of cancer’s block against the immune system. TetraLogic’s birinapant (TL32711) is a potent, bivalent SMAC-mimetic that binds with differential affinity to multiple members of the IAP family in order to re-establish the immune system’s ability to kill abnormal cells via an extracellular TNF signal. Merck’s KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 (programmed death receptor-1) and its ligands, PD-L1 and PD-L2. The proposed collaboration is based on preclinical data that suggest SMAC-mimetics have the potential to enhance existing immuno-oncology agents, such as KEYTRUDA.

“We are very excited to work with Merck to evaluate birinapant in combination with KEYTRUDA,” said J. Kevin Buchi, President and Chief Executive Officer of TetraLogic. “Both molecules are designed to help the body’s immune system better attack cancer cells, and we think the combination could be very promising.”

“We are establishing a broad base of clinical evidence with our anti-PD-1 therapy, KEYTRUDA, as monotherapy across different types of cancer,” said Dr. Eric Rubin, vice president and therapeutic area head, oncology early-stage development, Merck Research Laboratories. “We believe there is great potential to advance our clinical program and the field of immuno-oncology research through strategic collaborations and synergistic combinations, such as with KEYTRUDA and birinapant.”

Under the terms of the agreement, TetraLogic and Merck, through subsidiaries, will collaborate on an initial Phase 1 dose-escalation study of birinapant in combination with KEYTRUDA in patients with relapsed or refractory solid tumors. TetraLogic will sponsor and fund the study and Merck will provide KEYTRUDA. The companies have formed a Joint Development Committee to collaboratively oversee the conduct of the study. Results from the study will be used to determine the path for further clinical development of the combination.
- See more at: http://www.pharmacytimes.com/mar ... thash.VE4Kawxt.dpuf

StephenW

TetraLogic和默克合作开发Birinapant评价联合与KEYTRUDA（pembrolizumab）实体瘤
网上公布：周一，二○一五年四月二十○日
按照Pharmacy_Times：
新闻稿

宾夕法尼亚，MALVERN - KENILWORTH，新泽西州 - （BUSINESS WIRE） - TetraLogic制药公司（纳斯达克股票代码：TLOG），临床阶段的生物制药公司，专注于发现和培养在肿瘤学和传染病，以及默克新颖的小分子疗法（NYSE ：MRK），被称为美国以外的国家和加拿大MSD，今天宣布，他们已经进入了肿瘤临床研究协作。两家公司将合作在第1阶段研究，以评估birinapant的安全性和有效性，TetraLogic的SMAC-模拟，结合KEYTRUDA®（pembrolizumab），默克公司的抗PD-1的治疗，患者的复发或难治性实体肿瘤。这项研究预计于2015年末。

KEYTRUDA和对免疫系统癌症的块birinapant目标不同的元素。 TetraLogic的birinapant（TL32711）是一种强效，二价的SMAC模拟物，与差分亲和度对IAP家族的多个成员结合，以重新建立的免疫系统的能力，通过细胞外的TNF信号杀死异常细胞。默克的KEYTRUDA是人源化单克隆抗体阻断PD-1（程序性死亡受体-1）和它的配体PD-L1和PD-L2之间的相互作用。所提出的合作是基于建议的SMAC模拟物具有增强现有免疫肿瘤剂，如KEYTRUDA潜在临床前的数据。

“我们非常高兴能与工作默克评估birinapant与KEYTRUDA组合，”J.凯文步琪，总统和TetraLogic首席执行官说。 “这两种分子的目的是帮助人体免疫系统更好地攻击癌细胞，我们认为组合可能是非常有前途的。”

“我们正在建立的临床证据基础广泛与我们的抗PD-1治疗，KEYTRUDA，因为在不同类型的癌症单药治疗，”博士埃里克·鲁宾，副总裁和治疗领域的负责人，肿瘤早期发展阶段，默克公司表示，研究实验室。 “我们相信还有很大的潜力来推进我们的临床程序，并通过战略合作和协同组合，​​如与KEYTRUDA和birinapant免疫肿瘤学研究的领域。”

根据协议，TetraLogic和默克公司的条款，通过子公司，将合作birinapant的组合初始阶段1剂量递增研究与KEYTRUDA患者的复发或难治性实体肿瘤。 TetraLogic将赞助和资助研究和默克公司将提供KEYTRUDA。该公司已形成了联合发展委员会，以监督协作研究的开展。从研究结果将用于确定所述组合的进一步的临床发展的路径。
- 在查看更多： http://www.pharmacytimes.com/mar ... thash.VE4Kawxt.dpuf

StephenW

这是很有意思的, Keytruda是一种新的抗PD1抗癌药,从理论上讲，像Birinapant。能治疗乙肝.

StephenW

Hepatitis B Infection 100% Eliminated With Cancer Drug Combination In Preclinical Model
Apr 20, 2015 03:00 PM By Dana Dovey @danadovey
the liver
A new drug trial has promising results for hepatitis B treatment. Photo courtesy of
A cancer drug was 100 percent successful in clearing away hepatitis B infections in preclinical models for an Australian study. If researchers successfully replicate the results in human clinical trials, the drug may become the first-ever cure to the hepatitis B virus and may serve as a model for treating other viruses, such as HIV and herpes.

Researchers at the Walter and Eliza Hall Institute in Melbourne, Australia used a combination of the cancer drug birinapant and the antiviral drug entecavir to completely eliminate hepatitis B infections in “hundreds of tests in preclinical models,” lead researcher Dr. Marc Pellegrini explained in a press release. Human trials began in December 2014, and drug testing has currently moved on to a phase 1/2a in clinical trials.

Hepatitis B is a viral infection that attacks the liver. It is transmitted via contact with infected blood or bodily fluids and causes chronic liver infection, which may lead to life-threatening cirrhosis or liver cancer. According to the World Health Organization, there are an estimated 240 million people who are chronically infected with hepatitis B, and around 780,000 people die from complications due to their infection each year.

Although a vaccine against the virus has been available since 1982, treatment of those who are already infected is limited. This is because the virus is able to override the liver’s self-preservation mechanism. Normally, at the sign of infection, the liver will switch on a signal that tells cells to self-destruct in order to prevent further infection, Pelligrini explained. The hepatitis B virus destroys this communications switch and tells the cells to ignore rather than fight the infection. Birinapant is able to reverse this viral override, and restore the liver’s natural infection-fighting defense.

"Birinapant flips the cell survival 'switch' used by the virus, causing the infected cell to die," Pelligrini said.

The team also found that when birinapant was used in combination with entecavir, the infection was cleared twice as fast.

Drug resistance is an ever-present challenge for doctors when it comes to treating viruses. A virus learns to adapt to drugs and then becomes resistant to their defense. However, because the new combination indirectly attacks the virus by changing the way the body responds, this problem will most likely not exist.

“The virus relies on the survival mechanisms of the host, so if it can't exploit them, it dies. Such a monumental change in the virus's environment may be too big a hurdle for it to adapt to,” Pelegrini added.

The team believes the unique method in which the drug works could be used to explore effective treatments for other viruses such as HIV, herpes, dengue fever, and even bacterial infections such as tuberculosis.

Pellegrini, Dr. Greg Ebert, and their colleagues at the institute have published their research on the new drug combination in two papers in the online journal Proceedings of the National Academy of Sciences. Patients are being recruited to partake in the clinical trials in hospitals located in Perth and Adelaide, Australia.

Source: Pellegrini M, et al. Proceedings of the National Academy of Sciences. 2015.

StephenW

乙肝感染100％被淘汰随着癌症的药物组合在临床前模型
2015年4月20日03:00 PM通过多维达纳@danadovey
肝脏
一种新的药物试验有希望的结果为乙肝的治疗。图片提供
抗癌药是100％的成功扫清在临床前模型乙肝感染的澳大利亚研究。如果研究人员成功复制的结果，人体临床试验，该药有可能成为有史以来第一个治愈的乙肝病毒，可以作为一种模式用于治疗其他病毒，如艾滋病毒和疱疹。

研究人员在沃尔特伊丽莎堂研究院在澳大利亚墨尔本使用的抗癌药物birinapant和抗病毒药物恩替卡韦的组合，彻底消除乙肝感染“上百次试验在临床前模型，”首席研究员马克·佩莱格里尼博士的解释新闻稿。人体试验开始于2014年12月，和药物测试目前已就移动到1 ​​/ 2a上的相位在临床试验中。

B型肝炎是一种病毒感染，攻击肝脏。它是通过与受感染的血液或体液接触传播，引起慢性肝脏感染，这可能会导致威胁生命的肝硬化或肝癌。根据世界卫生组织，估计有2.4亿人谁是长期由于其感染感染乙肝，和周围78万人死于并发症每年。

虽然针对该病毒的疫苗自1982年以来一直使用，处理那些谁已经感染是有限的。这是因为，该病毒是能够覆盖肝脏的自我保护机制。通常情况下，在感染的迹象，肝脏将切换的信号，告诉细胞自我毁灭，以防止进一步的感染，Pelligrini说明。乙肝病毒破坏这种通信开关，并告诉细胞忽略，而不是对抗感染。 Birinapant能够扭转这种病毒覆盖，恢复肝脏的天然抗感染防御。

“Birinapant翻转使用的病毒的细胞存活'开关'，导致感染细胞死亡，”Pelligrini说。

研究小组还发现，当birinapant是与恩替卡韦联合使用，感染被清除快一倍。

耐药性，医生永远存在的挑战，当谈到治疗病毒。病毒学会适应药物，然后成为抵抗他们的防守。然而，由于新的组合间接通过改变身体反应的方式攻击病毒，这个问题将很可能不存在。

“该病毒依赖于宿主的生存机制，因此，如果不能利用它们，它死。在病毒的环境，如一个巨大的变化可能是太大的障碍让它适应，“Pelegrini补充。

该小组认为，独特的方法，其中药物作品可以用来探索有效治疗其他病毒，如HIV，疱疹，登革热，甚至细菌感染，如结核。

佩莱格​​里尼，格雷格·艾伯特博士，并在研究所的同事们发表了他们对新的药物组合的研究在美国国家科学院的在线杂志论文两篇论文。患者被招募的临床试验，以参加在位于珀斯和阿德莱德，澳大利亚的医院。

源：佩莱格里尼M等人。对美国国家科学院的诉讼。 2015年。

重韧

关键看疗效。。

战天斗hbv

股票今天上扬14%

newchinabok

前文写的很清楚  ：研究小组还发现，当birinapant是与恩替卡韦联合使用，感染被清除快一倍。  说人体有效果无疑，